Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
April 8, 2019CirculationOpen Access

Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The efficacy and safety of sacubitril/valsartan among patients hospitalized for acute decompensated heart failure was unknown.

Does sacubitril/valsartan improve clinical outcomes and reduce NT-proBNP in patients hemodynamically stabilized during hospitalization for acute decompensated heart failure compared to enalapril?

Population

Patients hemodynamically stabilized during hospitalization for acute decompensated heart failure

Comparison

Sacubitril/valsartan vs enalapril

Design

Randomized double-blind trial

Authors

DMDavid A. MorrowEVEric J. VelazquezADAdam D. DeVore

Discussion

Loading...

Member takes

Overview

Supports switching eligible HFrEF outpatients to sacubitril/valsartan; extends RCT evidence for ARNI over ACEI/ARB.

Structured PICO

Does sacubitril/valsartan improve clinical outcomes and reduce NT-proBNP in patients hemodynamically stabilized during hospitalization for acute decompensated heart failure compared to enalapril?

P
Population
Patients hemodynamically stabilized during hospitalization for acute decompensated heart failure (ADHF)
I
Intervention
Sacubitril/valsartan
C
Comparator
Enalapril
O
Outcome
N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration and a composite clinical end point of death, rehospitalization for HF, implantation of a left ventricular assist device, or listing for cardiac transplantationcomposite

In patients stabilized after acute decompensated heart failure, sacubitril/valsartan significantly reduces NT-proBNP and serious clinical events compared to enalapril.

Limitations

  • Analyses of clinical end points relied on investigator-reported data

Cite This Study

Morrow et al. (2019) studied this question.

synapsesocial.com/papers/6a7cffb7a3b6fd5035d59cc0https://doi.org/10.1161/circulationaha.118.039331
View Full Paper
Ask AI
Bookmark
Share